{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-028396","form_type":"8-K","ticker":"SNSE","cik":"0001829802","company_name":"Sensei Biotherapeutics, Inc.","filed_at":"2024-02-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.802215+00:00","generated_at":"2026-06-06T05:48:31.526304+00:00","sec_items":["5.02","8.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Director Samuel Broder resigns from Sensei Biotherapeutics board; board reduced to eight","bullets":["Samuel Broder, MD resigned from the Board effective February 5, 2024, not due to any disagreement with the Company.","Dr. Broder will remain as a consultant providing strategic guidance on science, clinical development, and regulatory pathways.","Board reduced from nine to eight directors effective February 6, 2024.","Bill Ringo appointed as Interim Chair of the Nominating and Corporate Governance Committee, effective immediately."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-028396","json":"https://secwatch.observer/filing/0001193125-24-028396.json","markdown":"https://secwatch.observer/filing/0001193125-24-028396.md","text":"https://secwatch.observer/filing/0001193125-24-028396.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829802/000119312524028396/0001193125-24-028396-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829802/000119312524028396/d778564d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T05:48:31.526304+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e4044f81d8","claim":"Samuel Broder resigned as Director at Sensei Biotherapeutics, Inc..","evidence_excerpt":"On February 5, 2024, after serving for nearly five years on the Board of Directors (the “Board”) of Sensei Biotherapeutics, Inc. (the “Company”), Samuel Broder, MD notified the Company of his decision to resign from the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1829802/000119312524028396/0001193125-24-028396-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}